Vinay Prasad

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5320299/publications.pdf

Version: 2024-02-01

331	9,153	66343	51608
papers	citations	42 h-index	86 g-index

334	334	334	12197
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Network Open, 2019, 2, e192535.	5.9	842
2	Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices. Implementation Science, 2014, 9, 1.	6.9	486
3	Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. JAMA Internal Medicine, 2017, 177, 1569.	5.1	333
4	A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices. Mayo Clinic Proceedings, 2013, 88, 790-798.	3.0	300
5	The high price of anticancer drugs: origins, implications, barriers, solutions. Nature Reviews Clinical Oncology, 2017, 14, 381-390.	27.6	289
6	The Strength of Association Between Surrogate End Points and Survival in Oncology. JAMA Internal Medicine, 2015, 175, 1389.	5.1	287
7	Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival. JAMA Internal Medicine, 2015, 175, 1992.	5.1	287
8	Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. JAMA Oncology, 2018, 4, 1093.	7.1	274
9	Five Years of Cancer Drug Approvals. JAMA Oncology, 2015, 1, 539.	7.1	271
10	Perspective: The precision-oncology illusion. Nature, 2016, 537, S63-S63.	27.8	236
11	Prespecified Falsification End Points. JAMA - Journal of the American Medical Association, 2013, 309, 241.	7.4	204
12	Precision oncology: origins, optimism, and potential. Lancet Oncology, The, 2016, 17, e81-e86.	10.7	190
13	Tisagenlecleucel â€" the first approved CAR-T-cell therapy: implications for payers and policy makers. Nature Reviews Clinical Oncology, 2018, 15, 11-12.	27.6	177
14	Reversals of Established Medical Practices. JAMA - Journal of the American Medical Association, 2012, 307, 37.	7.4	171
15	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. BMC Medicine, 2017, 15, 134.	5.5	169
16	Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. JAMA Network Open, 2020, 3, e200423.	5.9	148
17	A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. European Journal of Cancer, 2019, 106, 196-211.	2.8	127
18	The Frequency of Medical Reversal. Archives of Internal Medicine, 2011, 171, 1675.	3.8	114

#	Article	IF	Citations
19	Cancer Drugs Approved Based on Biomarkers and Not Tumor Typeâ€"FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. JAMA Oncology, 2018, 4, 157.	7.1	114
20	An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Internal Medicine, 2019, 179, 915.	5.1	107
21	Examining the Use of Realâ€World Evidence in the Regulatory Process. Clinical Pharmacology and Therapeutics, 2020, 107, 843-852.	4.7	99
22	Why cancer screening has never been shown to â€œsave livesâ€â€"and what we can do about it. BMJ, The, 2016, 352, h6080.	6.0	98
23	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. JAMA Oncology, 2021, 7, 728.	7.1	94
24	Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy. JAMA Oncology, 2018, 4, 994.	7.1	93
25	Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs. Mayo Clinic Proceedings, 2016, 91, 713-725.	3.0	91
26	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Seminars in Oncology, 2017, 44, 132-135.	2.2	90
27	Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials. JAMA Internal Medicine, 2019, 179, 642.	5.1	76
28	Colorectal Cancer Survival Gains and Novel Treatment Regimens. JAMA Oncology, 2015, 1, 787.	7.1	75
29	Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration. JAMA Oncology, 2019, 5, 887.	7.1	73
30	A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. ELife, 2019, 8, .	6.0	71
31	Observational studies often make clinical practice recommendations: an empirical evaluation of authors' attitudes. Journal of Clinical Epidemiology, 2013, 66, 361-366.e4.	5.0	64
32	FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019. JAMA Internal Medicine, 2020, 180, 912.	5.1	61
33	Oral Anticancer Drugs: How Limited Dosing Options and Dose Reductions May Affect Outcomes in Comparative Trials and Efficacy in Patients. Journal of Clinical Oncology, 2014, 32, 1620-1629.	1.6	60
34	The Use of Superlatives in Cancer Research. JAMA Oncology, 2016, 2, 139.	7.1	57
35	Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration. JAMA Internal Medicine, 2020, 180, 1108.	5.1	57
36	Mortality and Treatment Patterns Among Patients Hospitalized With Acute Cardiovascular Conditions During Dates of National Cardiology Meetings. JAMA Internal Medicine, 2015, 175, 237.	5.1	56

#	Article	IF	Citations
37	Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. JAMA Network Open, 2021, 4, e2138793.	5.9	54
38	Direct-to-Consumer Genetic Testing. JAMA - Journal of the American Medical Association, 2018, 319, 2377.	7.4	52
39	The Accelerated Approval of Oncologic Drugs. JAMA - Journal of the American Medical Association, 2014, 311, 353.	7.4	51
40	Do cancer drugs improve survival or quality of life?. BMJ: British Medical Journal, 2017, 359, j4528.	2.3	51
41	Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. JAMA Network Open, 2020, 3, e200363.	5.9	49
42	The Inferior Vena Cava Filter. JAMA Internal Medicine, 2013, 173, 493.	5.1	46
43	Authorship Inflation in Medical Publications. Inquiry (United States), 2015, 52, 004695801559831.	0.9	46
44	Chest Pain in the Emergency Department. Archives of Internal Medicine, 2012, 172, 1506.	3.8	44
45	Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter. JAMA Internal Medicine, 2017, 177, 425.	5.1	44
46	Media Coverage of Medical Journals: Do the Best Articles Make the News?. PLoS ONE, 2014, 9, e85355.	2.5	44
47	Real-world Evidenceâ€"What Does It Really Mean?. JAMA Oncology, 2019, 5, 781.	7.1	43
48	Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget, 2015, 6, 16766-16773.	1.8	42
49	Comparative Effectiveness Questions in Oncology. New England Journal of Medicine, 2014, 370, 1478-1481.	27.0	39
50	The Withdrawal of Drugs for Commercial Reasons. JAMA Internal Medicine, 2014, 174, 1887.	5.1	36
51	The Diagnosis and Treatment of Pulmonary Embolism. Archives of Internal Medicine, 2012, 172, 955-8.	3.8	35
52	Hard-Wired Bias. Mayo Clinic Proceedings, 2015, 90, 1171-1175.	3.0	35
53	Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 1639-1649.	3.0	34
54	US News and World Report Cancer Hospital Rankings: Do They Reflect Measures of Research Productivity?. PLoS ONE, 2014, 9, e107803.	2.5	33

#	Article	IF	Citations
55	The misguided ethics of crossover trials. Contemporary Clinical Trials, 2014, 37, 167-169.	1.8	33
56	Does the Declining Lethality of Gunshot Injuries Mask a Rising Epidemic of Gun Violence in the United States?. Journal of General Internal Medicine, 2014, 29, 1065-1069.	2.6	32
57	Blood-Based Screening for Colon Cancer. JAMA - Journal of the American Medical Association, 2016, 315, 2519.	7.4	31
58	Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. Oncologist, 2016, 21, 261-268.	3.7	30
59	Nusinersen for Spinal Muscular Atrophy. JAMA Pediatrics, 2018, 172, 123.	6.2	30
60	Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration. JAMA Internal Medicine, 2016, 176, 389.	5.1	29
61	Improving observational studies in the era of big data. Lancet, The, 2018, 392, 716-717.	13.7	29
62	A reality check of the accelerated approval of immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2019, 16, 656-658.	27.6	29
63	Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World. JAMA Oncology, 2017, 3, 889.	7.1	28
64	Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ: British Medical Journal, 2018, 360, k668.	2.3	28
65	Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ Open, 2018, 6, E31-E38.	2.4	27
66	Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018. JAMA Internal Medicine, 2021, 181, 162.	5.1	27
67	Industry Funding of Cancer Patient Advocacy Organizations. Mayo Clinic Proceedings, 2016, 91, 1668-1670.	3.0	26
68	Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. JAMA - Journal of the American Medical Association, 2016, 316, 271.	7.4	26
69	Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. JAMA Network Open, 2022, 5, e222265.	5.9	26
70	Drugs that lack single-agent activity: are they worth pursuing in combination?. Nature Reviews Clinical Oncology, 2017, 14, 193-194.	27.6	25
71	The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.. Translational Oncology, 2022, 18, 101374.	3.7	25
72	Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncology, The, 2021, 22, 11-13.	10.7	23

#	Article	IF	Citations
73	Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. Lancet Oncology, The, 2020, 21, 1134-1136.	10.7	22
74	The Effect of Hospital Visitor Policies on Patients, Their Visitors, and Health Care Providers During the COVID-19 Pandemic: A Systematic Review. American Journal of Medicine, 2022, 135, 1158-1167.e3.	1.5	22
75	The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem. Mayo Clinic Proceedings, 2016, 91, 707-712.	3.0	21
76	The Rising Price of Cancer Drugsâ€"A New Old Problem?. JAMA Oncology, 2017, 3, 277.	7.1	21
77	Reclaiming the morbidity and mortality conference: between Codman and Kundera. Medical Humanities, 2010, 36, 108-111.	1.2	20
78	A medical burden of proof: Towards a new ethic. BioSocieties, 2012, 7, 72-87.	1.3	20
79	Future jobs of FDAâ€™s haematology-oncology reviewers. BMJ, The, 2016, 354, i5055.	6.0	20
80	Conflicts of interest in Twitter. Lancet Haematology,the, 2017, 4, e408-e409.	4.6	20
81	Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. JAMA Network Open, 2021, 4, e2135123.	5.9	20
82	Non-inferiority trials: why oncologists must remain wary. Lancet Oncology, The, 2015, 16, 364-366.	10.7	19
83	Effect of the American Society of Clinical Oncologyâ€™s Conflict of Interest Policy on Information Overload. JAMA Oncology, 2016, 2, 1653.	7.1	19
84	A pooled analysis of published, basket trials in cancer medicine. European Journal of Cancer, 2018, 101, 244-250.	2.8	19
85	The role of censoring on progression free survival: Oncologist discretion advised. European Journal of Cancer, 2015, 51, 2269-2271.	2.8	18
86	Me-too drugs with limited benefits â€" the tale of regorafenib for HCC. Nature Reviews Clinical Oncology, 2017, 14, 653-654.	27.6	17
87	Low-value approvals and high prices might incentivize ineffective drug development. Nature Reviews Clinical Oncology, 2018, 15, 399-400.	27.6	17
88	Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations?. JAMA Network Open, 2020, 3, e2012119.	5.9	17
89	Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Nonâ€“Small Cell Lung Cancers. JAMA Network Open, 2020, 3, e202488.	5.9	17
90	Persistent challenges with treating multiple myeloma early. Blood, 2021, 137, 456-458.	1.4	17

#	Article	IF	Citations
91	Has the Current Oncology Value Paradigm Forgotten Patientsâ€™ Time?. JAMA Oncology, 2021, 7, 1757.	7.1	17
92	Are We Treating Professionalism Professionally? Medical School Behavior as Predictors of Future Outcomes. Teaching and Learning in Medicine, 2011, 23, 337-341.	2.1	16
93	How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. Blood, 2015, 126, 1860-1861.	1.4	16
94	Combining drugs and extending treatment â€" a PFS end point is not sufficient. Nature Reviews Clinical Oncology, 2017, 14, 521-522.	27.6	16
95	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence-Based Medicine, 2022, 27, 46-54.	3.5	16
96	The evidence landscape in precision medicine. Science Translational Medicine, 2020, 12, .	12.4	16
97	A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. European Journal of Cancer, 2018, 101, 143-151.	2.8	15
98	Why Randomized Controlled Trials Are Needed to Accept New Practices: 2 Medical Worldviews. Mayo Clinic Proceedings, 2013, 88, 1046-1050.	3.0	14
99	What constitutes an â€œunmet medical needâ€•in oncology? An empirical evaluation of author usage in the biomedical literature. Seminars in Oncology, 2017, 44, 8-12.	2.2	14
100	The Oncologic Drugs Advisory Committee Votes of April 2021â€"Implications for the Fate of Accelerated Approval. JAMA Oncology, 2021, 7, 1607-1609.	7.1	14
101	The Cardiovascular Biomarker Conundrum. JAMA - Journal of the American Medical Association, 2011, 306, 2151-2.	7.4	13
102	Cardiovascular Primary Prevention. Archives of Internal Medicine, 2012, 172, 656.	3.8	13
103	Publication Trends Among Internal Medicine Residents and Graduates. American Journal of Medicine, 2012, 125, 939-944.	1.5	13
104	Double-Crossed: Why Crossover in Clinical Trials May Be Distorting Medical Science. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 625-627.	4.9	13
105	The Peltzman effect and compensatory markers in medicine. Healthcare, 2014, 2, 170-172.	1.3	13
106	Choice of control group in randomised trials of cancer medicine: are we testing trivialities?. Lancet Oncology, The, 2018, 19, 1150-1152.	10.7	13
107	Case Reports in the Age of Twitter. American Journal of Medicine, 2019, 132, e725-e726.	1.5	13
108	Censored patients in Kaplanâ€“Meier plots of cancer drugs: An empirical analysis of data sharing. European Journal of Cancer, 2020, 141, 152-161.	2.8	13

#	Article	IF	Citations
109	Industry Relationships With Medical Oncologists: Who Are the High-Payment Physicians?. JCO Oncology Practice, 2022, 18, e1164-e1169.	2.9	13
110	Open Issues with Open Access Publication. American Journal of Medicine, 2013, 126, 563-564.	1.5	12
111	Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials?. Journal of Clinical Epidemiology, 2014, 67, 361-363.	5.0	12
112	Use of the Word â€œCureâ€•in the Oncology Literature. American Journal of Hospice and Palliative Medicine, 2015, 32, 477-483.	1.4	12
113	Precision medicine in acute myeloid leukemia: Hope, hype or both?. Leukemia Research, 2016, 48, 73-77.	0.8	12
114	Pharmaceutical Marketing for Rare Diseases. JAMA - Journal of the American Medical Association, 2017, 317, 2479.	7.4	12
115	The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: an observational study. CMAJ Open, 2018, 6, E57-E62.	2.4	12
116	Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. JAMA Network Open, 2019, 2, e1916091.	5.9	11
117	Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?. European Journal of Cancer, 2020, 139, 20-26.	2.8	11
118	The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years. JAMA Oncology, 2021, 7, 1569.	7.1	11
119	Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. Journal of Clinical Epidemiology, 2021, 139, 80-86.	5.0	11
120	Tebentafusp in first-line melanoma trials: An outperforming outlier. Translational Oncology, 2022, 20, 101408.	3.7	11
121	Clostridium difficile Diarrhea and Fecal Transplantation. Journal of Clinical Gastroenterology, 2011, 45, 742-743.	2.2	10
122	Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: A good thing?. European Journal of Cancer, 2015, 51, 2272-2274.	2.8	10
123	Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?. Cardiovascular Drugs and Therapy, 2018, 32, 633-635.	2.6	10
124	Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapyâ€”Reply. JAMA Oncology, 2018, 4, 1785.	7.1	10
125	Eliminating MRD â€” FDA approval of blinatumomab for B-ALL in complete remission. Nature Reviews Clinical Oncology, 2018, 15, 727-728.	27.6	10
126	The Necessity of Sham Controls. American Journal of Medicine, 2019, 132, e29-e30.	1.5	10

#	Article	IF	Citations
127	Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma. Journal of Cancer Policy, 2019, 21, 100189.	1.4	10
128	Pembrolizumab for Nonâ€“Muscle-Invasive Bladder Cancerâ€”A Costly Therapy in Search of Evidence. JAMA Oncology, 2021, 7, 501.	7.1	10
129	Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematology,the, 2021, 8, e299-e304.	4.6	10
130	The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. Leukemia and Lymphoma, 2021, 62, 2793-2795.	1.3	10
131	Can a Resident's Publication Record Predict Fellowship Publications?. PLoS ONE, 2014, 9, e90140.	2.5	10
132	Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. Translational Oncology, 2022, 15, 101248.	3.7	10
133	Lacking the Incentive to Cure? Recurring Clostridium difficile Diarrhea and Our Reluctance to Use Fecal Transplantation. Journal of Clinical Gastroenterology, 2011, 45, 379-380.	2.2	9
134	Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?. Cmaj, 2015, 187, E276-E278.	2.0	9
135	Do we need randomised trials for rare cancers?. European Journal of Cancer, 2015, 51, 1355-1357.	2.8	9
136	Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology and Therapy, 2015, 16, 1014-1018.	3.4	9
137	Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. European Journal of Heart Failure, 2016, 18, 128-132.	7.1	9
138	Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy?. Journal of General Internal Medicine, 2018, 33, 3-5.	2.6	9
139	Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration. JAMA Internal Medicine, 2018, 178, 743.	5.1	9
140	Multiplicity in oncology randomised controlled trials: a threat to medical evidence?. Lancet Oncology, The, 2019, 20, 1638-1640.	10.7	9
141	Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. Future Science OA, 2020, 6, FSO600.	1.9	9
142	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. European Urology, 2021, 79, 710-712.	1.9	9
143	Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. European Journal of Cancer, 2021, 156, 164-174.	2.8	9
144	Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 428-433.	4.9	9

#	Article	IF	Citations
145	Trends in drug revenue among major pharmaceutical companies: A 2010â€2019 cohort study. Cancer, 2022, 128, 311-316.	4.1	9
146	Synthetic control arms in studies of multiple myeloma and diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2022, 196, 1274-1277.	2.5	9
147	Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022. JAMA Network Open, 2022, 5, e2216058.	5.9	9
148	Perspective: Beyond Storytelling in Medicine: An Encounter-Based Curriculum. Academic Medicine, 2010, 85, 794-798.	1.6	8
149	Handheld Ultrasounds: Pocket Sized, but Pocket Ready?. American Journal of Medicine, 2013, 126, 845-846.	1.5	8
150	Translation failure and medical reversal: Two sides to the same coin. European Journal of Cancer, 2016, 52, 197-200.	2.8	8
151	Overestimating the Benefit of Cancer Drugs. JAMA Oncology, 2017, 3, 1737.	7.1	8
152	Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?. Cancer, 2020, 126, 4087-4088.	4.1	8
153	Shifting, overlapping and expanding use of â€œprecision oncologyâ€•terminology: a retrospective literature analysis. BMJ Open, 2020, 10, e036357.	1.9	8
154	Comparison of Industry Payments in 2017 With Annual Salary in a Cohort of Academic Oncologists. JAMA Internal Medicine, 2020, 180, 797.	5.1	8
155	The response rate of alternative treatments for drugs approved on the basis of response rate. International Journal of Cancer, 2021, 148, 713-722.	5.1	8
156	But how many people died? Health outcomes in perspective. Cleveland Clinic Journal of Medicine, 2015, 82, 146-150.	1.3	8
157	Characteristics of Cluster Randomized Trials: Are They Living Up to the Randomized Trial?. JAMA Internal Medicine, 2013, 173, 313.	5.1	7
158	Evaluating Health System Processes With Randomized Controlled Trials. JAMA Internal Medicine, 2013, 173, 1279.	5.1	7
159	Negative trials in ovarian cancer: is there such a thing as too much optimism?. Ecancermedicalscience, 2016, 10, ed58.	1.1	7
160	Meaningful and Accurate Disclosure of Conflict of Interest at the ASTRO National Meeting: A Need for Reassessment of Current Policies. Journal of Oncology Practice, 2018, 14, e692-e698.	2.5	7
161	Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. BMJ: British Medical Journal, 2018, 362, k3783.	2.3	7
162	A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2303-2311.	2.5	7

#	Article	IF	Citations
163	Assessment of Accuracy of Waterfall Plot Representations of Response Rates in Cancer Treatment Published in Medical Journals. JAMA Network Open, 2019, 2, e193981.	5.9	7
164	Should Evidence Come with an Expiration Date?. Journal of General Internal Medicine, 2019, 34, 1356-1357.	2.6	7
165	Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19. Nature Reviews Clinical Oncology, 2021, 18, 7-8.	27.6	7
166	Approval and Coverage of Cancer Drugs in England, Canada, and the US. JAMA Internal Medicine, 2021, 181, 509.	5.1	7
167	Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?. European Journal of Clinical Investigation, 2021, 51, e13580.	3.4	7
168	Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. European Journal of Cancer, 2021, 155, 163-167.	2.8	7
169	How the US Food and Drug Administrationâ€™s approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. European Journal of Cancer, 2021, 157, 68-70.	2.8	7
170	High US drug prices have global implications. BMJ, The, 2022, 376, o693.	6.0	7
171	Targeted therapy in lung cancer: Are we closing the gap in years of life lost?. Cancer Medicine, 2022, 11, 3417-3424.	2.8	7
172	Duty Hour Reform in a Shifting Medical Landscape. Journal of General Internal Medicine, 2013, 28, 1238-1240.	2.6	6
173	Counterpoint: Were Industry-Sponsored Roflumilast Trials Appropriate? No. Chest, 2014, 145, 939-942.	0.8	6
174	Same Data; Different Interpretations. Journal of Clinical Oncology, 2016, 34, 3729-3732.	1.6	6
175	Thinking Systematically About the Offâ€Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. Oncologist, 2016, 21, 1031-1032.	3.7	6
176	Assessing Pharmaceutical Research and Development Costsâ€”Reply. JAMA Internal Medicine, 2018, 178, 588.	5.1	6
177	Low-Dose Computed Tomographic Screening for Lung Cancer: Time to Implement or Unresolved Questions?. Journal of General Internal Medicine, 2021, 36, 3202-3204.	2.6	6
178	Overall survival for oncology drugs approved for genomic indications. European Journal of Cancer, 2022, 160, 175-179.	2.8	6
179	Characteristics of oncology podcasts: Attitudes, speakers, conflicts. Journal of Cancer Policy, 2022, 32, 100329.	1.4	6
180	Persistent reservations against the premedical and medical curriculum. Perspectives on Medical Education, 2022, 2, 335-339.	3.5	5

#	Article	IF	Citations
181	Modern Drug Development. JAMA - Journal of the American Medical Association, 2014, 312, 2619.	7.4	5
182	Statins, Primary Prevention, and Overall Mortality. Annals of Internal Medicine, 2014, 160, 867.	3.9	5
183	Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. European Journal of Cancer, 2015, 51, 2718-2723.	2.8	5
184	Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals. Blood Cancer Journal, 2017, 7, 637.	6.2	5
185	Clinically meaningful benefit: real world use compared against the American and European guidelines. Blood Cancer Journal, 2017, 7, 645.	6.2	5
186	Overall Survival vs Disease-Specific Survivalâ€”Reply. JAMA Oncology, 2018, 4, 586.	7.1	5
187	Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?. European Journal of Cancer, 2018, 104, 252-253.	2.8	5
188	Testing Healthcare Workers for Latent Tuberculosis: Is It Evidence Based, Bio-Plausible, Both, Or Neither?. American Journal of Medicine, 2019, 132, 1260-1261.	1.5	5
189	The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. JAMA Internal Medicine, 2020, 180, 315.	5.1	5
190	News Coverage of the American Cancer Societyâ€™s Update to Colorectal Cancer Screening Guidelines. Mayo Clinic Proceedings, 2020, 95, 617-618.	3.0	5
191	Industry payments to US physicians for cancer therapeutics: An analysis of the 2016â€“2018 open payments datasets. Journal of Cancer Policy, 2021, 28, 100283.	1.4	5
192	The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009â€“2018. BMC Cancer, 2021, 21, 889.	2.6	5
193	Comparison of Classification of Indications for Allogeneic and Autologous Transplant for Adults in ASTCT Guidelines and Evidence Available in Published Literature. JAMA Internal Medicine, 2021, , .	5.1	5
194	The overdiagnosis of pneumonia. Cleveland Clinic Journal of Medicine, 2013, 80, 616-618.	1.3	5
195	Dense breasts and legislating medicine. Cleveland Clinic Journal of Medicine, 2013, 80, 768-770.	1.3	5
196	An Unmeasured Harm of Screening. Archives of Internal Medicine, 2012, 172, 1442.	3.8	4
197	Wearables, Smartphones and Novel Anticoagulants: We Will Treat More Atrial Fibrillation, but Will Patients Be Better Off?. Journal of General Internal Medicine, 2016, 31, 1367-1368.	2.6	4
198	Pembrolizumab as firstâ€line therapy in programmed death ligand 1â€“positive advanced lung cancer: Is it as effective as we think it is?. Cancer, 2017, 123, 3872-3874.	4.1	4

#	Article	IF	Citations
199	Unanticipated Outcomes: A Medical Memoirâ€"A Book Review. JAMA Internal Medicine, 2018, 178, 11.	5.1	4
200	The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another. American Journal of Medicine, 2019, 132, e509-e511.	1.5	4
201	Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington. JAMA Internal Medicine, 2020, 180, 329.	5.1	4
202	Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administrationâ€™s Actions. Mayo Clinic Proceedings, 2020, 95, 424-426.	3.0	4
203	Application of ASCO Value Framework to Treatment Advances in Hepatocellular Carcinoma. JCO Oncology Practice, 2021, 17, OP.20.00558.	2.9	4
204	Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer. JAMA Network Open, 2021, 4, e2124728.	5.9	4
205	The frequency of assessment of progression in randomized oncology clinical trials. Cancer Reports, 2022, 5, e1527.	1.4	4
206	Retrospective comparative effectiveness research: will changing the analytical methods change the results?. International Journal of Cancer, 2022, , .	5.1	4
207	Reporting of Physiciansâ€™ or Investigatorsâ€™ Choice of Treatment in Oncology Randomized Clinical Trials. JAMA Network Open, 2022, 5, e2144770.	5.9	4
208	Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. European Journal of Cancer, 2022, , .	2.8	4
209	Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Antiâ€“PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial. Journal of Clinical Oncology, 2022, 40, 1596-1597.	1.6	4
210	Where are randomized trials necessary: Are smoking and parachutes good counterexamples?. European Journal of Clinical Investigation, 2022, 52, e13730.	3.4	4
211	Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials. JAMA Network Open, 2022, 5, e2212327.	5.9	4
212	Treatment of Moderate to Severe Hidradenitis Suppurativa. Annals of Internal Medicine, 2013, 159, 72.	3.9	3
213	In reply Iâ€"Reversal of Medical Practices. Mayo Clinic Proceedings, 2013, 88, 1183-1184.	3.0	3
214	The Declining Demand for Hospital Care as a Rationale for Duty Hour Reform. Journal of General Internal Medicine, 2014, 29, 1400-1403.	2.6	3
215	Regarding Empiricism and Rationalism in Medicine and 2ÂMedical Worldviews. Mayo Clinic Proceedings, 2014, 89, 137.	3.0	3
216	The Reply. American Journal of Medicine, 2014, 127, e21.	1.5	3

#	Article	IF	Citations
217	Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?. Medical Hypotheses, 2016, 93, 71-73.	1.5	3
218	ASCO Plenary Sessions: impact, legacy, future. Seminars in Oncology, 2016, 43, 321-326.	2.2	3
219	Application of Medicareâ€™s New Technology Add-on Payment Program for Blinatumomab. JAMA Oncology, 2016, 2, 165.	7.1	3
220	Use of word â€œunprecedentedâ€•in the media coverage of cancer drugs: Do â€œunprecedentedâ€•drugs live up to the hype?. Journal of Cancer Policy, 2017, 14, 16-20.	1.4	3
221	Limitations Concerning the Association of Physician Sex and Patient Outcomes. JAMA Internal Medicine, 2017, 177, 1058.	5.1	3
222	Taking Care of Our Friends and Neighbors. JAMA Oncology, 2017, 3, 16.	7.1	3
223	Multivitamins Do Not Reduce Cardiovascular Disease and Mortality and Should Not Be Taken for This Purpose. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004886.	2.2	3
224	Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?. Mayo Clinic Proceedings, 2019, 94, 951-956.	3.0	3
225	Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours. Current Oncology, 2019, 26, 791-792.	2.2	3
226	Where Does the Blame for High Health Care Costs Go? An Empirical Analysis of Newspaper and Journal Articles Criticizing Health Care Costs. American Journal of Medicine, 2019, 132, 718-721.	1.5	3
227	Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. Leukemia Research, 2020, 96, 106420.	0.8	3
228	A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer. Trends in Cancer, 2020, 6, 736-738.	7.4	3
229	US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. Cancer, 2020, 126, 4270-4272.	4.1	3
230	Drug Approvals in Hepatocellular Carcinomaâ€”Filling the Nonexistent Gap?. JAMA Oncology, 2021, 7, 173.	7.1	3
231	Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. JTO Clinical and Research Reports, 2021, 2, 100149.	1.1	3
232	Assessment of New Molecular Entities Approved for Cancer Treatment in 2020. JAMA Network Open, 2021, 4, e2112558.	5.9	3
233	Accurate accounting of caplacizumab cost effectiveness. Lancet Haematology,the, 2021, 8, e315.	4.6	3
234	Idecabtagene vicleucel: questions regarding the appropriate role and cost. British Journal of Haematology, 2022, 196, .	2.5	3

#	Article	IF	Citations
235	Multi-cancer screening tests: communicating about risks should be prioritized.. American Journal of Medicine, 2021, , .	1.5	3
236	Cancer screening: A modest proposal for prevention. Cleveland Clinic Journal of Medicine, 2019, 86, 157-160.	1.3	3
237	Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more. Annals of Gastroenterology, 2013, 26, 277-278.	0.6	3
238	Quality of biomarker defined subgroups in <scp>FDA</scp> approvals of <scp>PD</scp>â€1/<scp>PDâ€L1</scp> inhibitors 2014 to 2020. International Journal of Cancer, 2022, 150, 1905-1910.	5.1	3
239	Caution Needed When Predicting Problem Residents. Academic Medicine, 2011, 86, 2.	1.6	2
240	Falsification End Points for Observational Studiesâ€”Reply. JAMA - Journal of the American Medical Association, 2013, 309, 1769.	7.4	2
241	It Is Time to Stop Screening for Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1841.	5.1	2
242	Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?. Journal of Cancer Research and Clinical Oncology, 2014, 140, 521-524.	2.5	2
243	Observational Studies Cannot Justify the Inferior Vena Cava Filter. American Journal of Medicine, 2014, 127, e15.	1.5	2
244	The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary; does it also improve survival?. European Journal of Cancer, 2016, 54, 159-162.	2.8	2
245	A further strategy to combat the high price of anticancer drugs. Nature Reviews Clinical Oncology, 2017, 14, 629-629.	27.6	2
246	Is â€œDo Everything!â€•Always Appropriate?â€”Reply. JAMA Oncology, 2017, 3, 1588.	7.1	2
247	PFO closure for secondary stroke prevention: is the discussion closed?. Journal of Thrombosis and Thrombolysis, 2018, 46, 74-76.	2.1	2
248	Inconsistent Reporting of Potential Conflicts of Interest. JAMA Oncology, 2018, 4, 1439.	7.1	2
249	Why is research in early-stage cancer research so low?. Journal of Cancer Policy, 2018, 17, 4-8.	1.4	2
250	Cost-effectiveness of Nusinersen for Spinal Muscular Atrophyâ€”Reply. JAMA Pediatrics, 2018, 172, 701.	6.2	2
251	Testing for blinding in sham-controlled studies for procedural interventions: the third-party video method. Cmaj, 2019, 191, E272-E273.	2.0	2
252	Registration studies â€” when should patients be deemed ineligible for aggressive therapy?. Nature Reviews Clinical Oncology, 2019, 16, 333-334.	27.6	2

#	Article	IF	Citations
253	Replacing the NCCNâ€™s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?. Pharmacoeconomics, 2020, 38, 729-731.	3.3	2
254	An Analysis of 5ÂYears of Randomized Trials in Gastroenterology and Hepatology Reveals 52 Medical Reversals. Digestive Diseases and Sciences, 2022, 67, 2011-2018.	2.3	2
255	Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination. Frontiers of Medicine, 2021, 15, 938-941.	3.4	2
256	Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015â€“2020. Journal of Cancer Policy, 2021, 30, 100311.	1.4	2
257	An estimate of rate of deviation from NCCN guideline recommendations forÂcentral nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC). BMC Cancer, 2022, 22, 70.	2.6	2
258	The accelerated approval pathway in oncology: Balancing the benefits and potential harms.. Journal of Cancer Policy, 2022, 32, 100323.	1.4	2
259	The Kardashian Index: a study of researchers' opinions on twitter 2014â€“2021. Scientometrics, 2022, 127, 1923-1930.	3.0	2
260	Baseline event rate, the Concorde fallacy, and the topography of cardiac risk. Medical Hypotheses, 2010, 75, 639-641.	1.5	1
261	Steroids in infection: an old wives' tale. Cmaj, 2011, 183, 83-83.	2.0	1
262	Firearm Legislation and Gun-Related Fatalities. JAMA Internal Medicine, 2013, 173, 2011.	5.1	1
263	Long-term Effects of the 2003 ACGME Resident Duty Hour Reform on Hospital Mortality. Mayo Clinic Proceedings, 2014, 89, 1023-1025.	3.0	1
264	Emphasizing unique strengths and eliminating redundancy for research in lowâ€income and middleâ€income countries: Lessons from a South American country. Cancer, 2015, 121, 2668-2670.	4.1	1
265	Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5ÂYears of Statin Meta-Analyses. American Journal of Cardiovascular Drugs, 2015, 15, 379-386.	2.2	1
266	Reply to Dr. Leon: true but unrelated. Journal of Clinical Epidemiology, 2016, 75, 127.	5.0	1
267	Precision medicine in diffuse large B-cell lymphoma: Hype or hope?. European Journal of Cancer, 2016, 68, 22-26.	2.8	1
268	How the USPSTF's Mammographic Screening Guidelines Should Be Interpreted. American Journal of Medicine, 2017, 130, 769-770.	1.5	1
269	Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studiesâ€”Reply. JAMA Oncology, 2018, 4, 1300.	7.1	1
270	The US Food and Drug Administrationâ€™s use of pathologic complete response as regulatory endpoint: Did it pay off?. Journal of Cancer Policy, 2018, 16, 49-51.	1.4	1

#	Article	IF	Citations
271	Inconsistent Reporting of Potential Conflicts of Interest. JAMA Internal Medicine, 2018, 178, 1424.	5.1	1
272	If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis. Journal of General Internal Medicine, 2018, 33, 1213-1214.	2.6	1
273	A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 19-22.	2.3	1
274	Medical reversals in lowâ€•and middleâ€•income countries. International Journal of Health Planning and Management, 2020, 35, 631-638.	1.7	1
275	Response to Comment on â€œReplacing the NCCNâ€™s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?â€• Pharmacoeconomics, 2020, 38, 895-896.	3.3	1
276	Drug repurposing in oncology â€“ Authors' reply. Lancet Oncology, The, 2020, 21, e544.	10.7	1
277	Frequency of Medical Reversal Among Published Randomized Controlled Trials Assessing Cardiopulmonary Resuscitation (CPR). Mayo Clinic Proceedings, 2020, 95, 889-910.	3.0	1
278	Medical Reversals in Family Practice: A Review. Current Therapeutic Research, 2020, 92, 100579.	1.2	1
279	Statistical significance and clinical evidence â€“ Authors' reply. Lancet Oncology, The, 2020, 21, e119.	10.7	1
280	The regulatory saga of fedratinib. Journal of Oncology Pharmacy Practice, 2021, 27, 107815522110160.	0.9	1
281	N of 1 Data Sharing: The Impact of Data Sharing within the Hematologyâ€“Oncology Drug Products Division of the US FDA. Trends in Cancer, 2021, 7, 395-399.	7.4	1
282	Multiple myeloma triplet therapies: baseline characteristics and control groups. Lancet, The, 2021, 397, 1620-1621.	13.7	1
283	When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100. BMJ Evidence-Based Medicine, 2022, 27, 151-152.	3.5	1
284	After <scp>COVID</scp>â€•19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems. International Journal of Cancer, 2021, 149, 1723-1724.	5.1	1
285	New drugs and options can enhance patient outcomes: But can they also erode them?. European Journal of Cancer, 2021, 154, 1-3.	2.8	1
286	The FDAâ€™s latest move to expand eligibility for oncology trials â€” a double-edged sword?. Nature Reviews Clinical Oncology, 2021, 18, 745-746.	27.6	1
287	The apples and oranges of cost-effectiveness. Cleveland Clinic Journal of Medicine, 2012, 79, 377-379.	1.3	1
288	Colorectal cancer screening at a younger age: pitfalls in the model-based recommendation of the USPSTF. BMJ Evidence-Based Medicine, 2022, 27, 206-208.	3.5	1

#	Article	IF	Citations
289	Powering cancer screening for overall mortality. Ecancermedicalscience, 2013, 7, ed27.	1.1	1
290	A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers. Journal of Cancer Policy, 2022, 31, 100319.	1.4	1
291	Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TVâ€™s The Resident. European Journal of Emergency Medicine, 2022, 29, 142-143.	1.1	1
292	Post-protocol therapy and informative censoring in the CANDOR study. Lancet Oncology, The, 2022, 23, e97.	10.7	1
293	The use and meaning of the parachute metaphor in biomedicine: a citation analysis of a systematic review and a randomized trial of the parachute for freefall. Journal of Comparative Effectiveness Research, 2022, 11, 383-390.	1.4	1
294	An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough?. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 161-167.	4.9	1
295	Accelerated approval requirements for lurbinectedin. Lancet Oncology, The, 2022, 23, e206.	10.7	1
296	Multiplicity: When many analytic plans are applied or many redundant studies are run, falseâ€positive results are ensured. European Journal of Clinical Investigation, 2022, 52, e13802.	3.4	1
297	Common misconceptions of randomized controlled trials in oncology. European Journal of Clinical Investigation, 2022, 52, .	3.4	1
298	Perspective: Why There Must Be a Meditative Medicine. Alternative and Complementary Therapies, 2011, 17, 274-278.	0.1	0
299	Raise the Bar Even Higher for Primary Prevention Interventionsâ€”Reply. Archives of Internal Medicine, 2012, 172, 1352.	3.8	0
300	Freedom to Innovate: The Perils of Centralized Medical Researchâ€”Reply. Archives of Internal Medicine, 2012, 172, 1692.	3.8	0
301	The facts are the facts. Cmaj, 2012, 184, 2029-2030.	2.0	0
302	The Reply. American Journal of Medicine, 2013, 126, e45.	1.5	0
303	Taking care of sick patients. Cmaj, 2013, 185, 1008-1008.	2.0	0
304	Why resident physicians stay late. Cmaj, 2013, 185, 1184-1184.	2.0	0
305	Routine Noninvasive Testing and Highly Sensitive Troponin Immunoassaysâ€”Reply. JAMA Internal Medicine, 2013, 173, 834.	5.1	0
306	The Inferior Vena Cava Filterâ€”Reply. JAMA Internal Medicine, 2013, 173, 1754.	5.1	0

#	Article	IF	Citations
307	Further Thoughts on Why There Are Good Data Supporting the Inferior Vena Cava Filter. JAMA Internal Medicine, 2014, 174, 164.	5.1	0
308	The Reply. American Journal of Medicine, 2014, 127, e15.	1.5	0
309	Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesnâ€™t?. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1353-1357.	2.5	0
310	Rebuttal From Dr Rho et al. Chest, 2014, 145, 943-944.	0.8	0
311	Roflumilast in COPD: Response. Chest, 2015, 148, e31-e32.	0.8	0
312	Susan Bates, M.D., and Antonio â€œTitoâ€•Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute. Oncologist, 2015, 20, 1344-1346.	3.7	0
313	Pricing and Value of Cancer Drugsâ€”Reply. JAMA Oncology, 2015, 1, 842.	7.1	0
314	Balancing Accelerated Approval for Drugs With Accelerated Withdrawalâ€”Reply. JAMA Internal Medicine, 2016, 176, 567.	5.1	0
315	In Replyâ€”Is There a Need for â€œBias Policeâ€•in Industry-Sponsored Research?. Mayo Clinic Proceedings, 2016, 91, 121.	3.0	0
316	Moving Precision Oncology Forward Amid Myths and Misconceptionsâ€”Reply. JAMA Oncology, 2018, 4, 1790.	7.1	0
317	Addendum: Low-value approvals and high prices might incentivize ineffective drug development. Nature Reviews Clinical Oncology, 2018, 15, 787-787.	27.6	0
318	Inconsistent Reporting of Potential Conflicts of Interest. JAMA Pediatrics, 2018, 172, 886.	6.2	0
319	Concerning survival signal for eltrombopag in MDS/AML. Leukemia and Lymphoma, 2020, 61, 1002-1003.	1.3	0
320	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2022, 5, 98-99.	0.3	0
321	Old-fashioned Intelligence Will Always Be Needed in Medicine. European Urology Focus, 2021, 7, 685-686.	3.1	0
322	The implications of Industry-Funded Disease Awareness Campaigns in the Rare Disease Setting. Mayo Clinic Proceedings, 2021, 96, 2305-2308.	3.0	0
323	An Empirical Analysis of Precision Previvorship: Are Familial and High-Risk Cancer Preventive Programs Evidence-Based?. American Journal of Medicine, 2021, , .	1.5	0
324	The apples and oranges of cost-effectiveness: A rejoinder. Cleveland Clinic Journal of Medicine, 2012, 79, 610-611.	1.3	0

#	Article	IF	Citations
325	Disease Specific Productivity of American Cancer Hospitals. PLoS ONE, 2015, 10, e0121233.	2.5	0
326	Why Is Research in Early-Stage Cancer Research so Low? A Re-Assessment of Budish, Roin and Williams (2015). SSRN Electronic Journal, 0, , .	0.4	0
327	Elacestrant in metastatic breast cancer: Is the â€œstandard of careâ€•meeting standard requirements?. Translational Oncology, 2022, 15, 101273.	3.7	0
328	Artificial intelligence and magnetic resonance imaging may not make cancer screening better. Journal of Cancer Policy, 2022, 31, 100314.	1.4	0
329	Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer, 2022, 164, 95-104.	2.8	0
330	FDA precedents in drug approvals: Contradiction in promoting more treatment options. European Journal of Cancer, 2022, 169, 123-125.	2.8	0
331	General payments from Biogen to U.S. physicians between 2015 and 2020. Journal of the American Geriatrics Society, 2022, 70, 3035-3038.	2.6	0